Sexual response research
A synthetic melanocortin receptor agonist (bremelanotide) studied for central pathways involved in sexual arousal and desire, distinct from vascular-targeted compounds.
Quantity
Dose
Women's research notes
PT-141 is among the most extensively studied peptides in women's sexual health research, with phase 3 clinical trials in pre-menopausal women with hypoactive sexual desire disorder leading to FDA approval of bremelanotide in 2019.
The RECONNECT phase 3 program studied bremelanotide in pre-menopausal women diagnosed with HSDD, with co-primary endpoints measuring desire and distress. Published trials reported statistically significant improvements versus placebo across both endpoints.
Unlike PDE5 inhibitors that act on vascular pathways, PT-141 acts centrally on melanocortin receptors (notably MC4R) implicated in sexual desire circuits. This mechanism makes it a frequent reference compound in female sexual response research, where vascular-only approaches have shown limited efficacy.
Research has extended into post-menopausal cohorts and exploratory work on arousal disorder subtypes. Pre-clinical female models continue to map melanocortin signaling across the hypothalamic circuits involved in sexual motivation.
